Blood pressure lowering efficacy of dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonists compared to glucagon-like peptide-1 (GLP-1) receptor agonists.

IF 8.8 2区医学 Q1 MEDICINE, GENERAL & INTERNAL

Cochrane Database of Systematic Reviews Pub Date : 2025-04-16 DOI:10.1002/14651858.CD016144

Guillaume Grenet, Arthur Gougeon, Douglas M Salzwedel, Ciprian D Jauca, James M Wright

引用次数: 0

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To compare the blood pressure effects of dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonists with the blood pressure effects of glucagon-like peptide-1 (GLP-1) receptor agonists.

查看原文本刊更多论文

双糖依赖性胰岛素性多肽/胰高血糖素样肽-1 （GIP/GLP-1）受体激动剂与胰高血糖素样肽-1 （GLP-1）受体激动剂的降压效果比较

目的：这是Cochrane综述（干预）的一个方案。目的如下：比较双糖依赖性胰岛素性多肽/胰高血糖素样肽-1 （GIP/GLP-1）受体激动剂与胰高血糖素样肽-1 （GLP-1）受体激动剂的血压作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cochrane Database of Systematic Reviews 医学-医学：内科

CiteScore

10.60

自引率

2.40%

发文量

173

审稿时长

1-2 weeks

期刊介绍： The Cochrane Database of Systematic Reviews (CDSR) stands as the premier database for systematic reviews in healthcare. It comprises Cochrane Reviews, along with protocols for these reviews, editorials, and supplements. Owned and operated by Cochrane, a worldwide independent network of healthcare stakeholders, the CDSR (ISSN 1469-493X) encompasses a broad spectrum of health-related topics, including health services.